| 1 |
35110965 | Treatment Response to Immunotherapy After Crizotinib Resistance in a Patient With Pulmonary Sarcomatoid Carcinoma Harboring MET Exon 14 Skipping Mutation: A Case Report. | 2022 |
1 |
| 2 |
35405360 | Investigation on the survival implications of PD-L1 expression status in ALK- rearranged advanced non-small cell lung cancer treated with first-line crizotinib. | 2022 May |
5 |
| 3 |
34428672 | Multiplexed electrokinetic sensor for detection and therapy monitoring of extracellular vesicles from liquid biopsies of non-small-cell lung cancer patients. | 2021 Dec 1 |
1 |
| 4 |
32386255 | Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib. | 2020 Aug |
6 |
| 5 |
31098955 | PD-L1 Expression and Its Regulation in Lung Adenocarcinoma with ALK Translocation. | 2019 Jun |
2 |
| 6 |
28978110 | Increased PD-L1 expression in erlotinib-resistant NSCLC cells with MET gene amplification is reversed upon MET-TKI treatment. | 2017 Sep 15 |
1 |
| 7 |
27141355 | Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients. | 2016 Mar |
2 |
| 8 |
27141364 | EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1α and STAT3. | 2016 Mar |
3 |
| 9 |
27753543 | STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer. | 2016 Dec 16 |
1 |